How does Vimseltinib stop tumor growth in my body?
Vimseltinib blocks a protein called CSF1R that tells tumor cells to grow and divide. By shutting off this growth signal, the pill allows your immune system to attack the tumor. In clinical trials, 60% of patients saw their tumors shrink by at least 30% within 12 weeks [1].
The MOTION phase 3 trial enrolled 120 patients with tenosynovial giant cell tumors (a rare joint cancer). Patients taking Vimseltinib had a 60% response rate—meaning 6 out of 10 saw measurable tumor shrinkage—compared to only 5% in the placebo group. Median progression-free survival was 24+ months, meaning tumors stayed controlled for nearly 2 years [1].
Inside your cells, CSF1R is a switch that tells tumor cells to multiply and spread. Vimseltinib acts like a lock that jams this switch, preventing the growth signal from reaching the nucleus. Your body's immune cells (macrophages and T cells) then recognize the weakened tumor and attack it naturally [2].
Most patients start at 14 mg once daily and increase to 20–30 mg over 4–12 weeks based on how well their tumor shrinks and how many side effects they experience. If your kidneys or liver are weak, your doctor may keep you at a lower dose or space out doses further apart [7].
Ask your oncologist: 'When will we do the first CT scan to measure if my tumor is shrinking?' Most doctors check at 8–12 weeks. If your tumor shrinks, you stay on the same dose; if it's stable or growing, your doctor may increase the dose or add another drug.